Kah Kee Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kah Kee Tan has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Chuin-Hen Liew
Department of Pediatrics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
8 shared publications - David Chun-Ern Ng
Hospital Tuanku Ja'afar Seremban Negeri Sembilan Malaysia
8 shared publications - Ling Chin
Department of Pediatrics Hospital Tuanku Ja'afar Seremban Seremban Malaysia
5 shared publications - Erwin Jiayuan Khoo
Department of Paediatrics, School of Medicine, IMU University, Kuala Lumpur, Malaysia
4 shared publications - Marlindawati Mohd Ali
Hospital Tuanku Ja'afar, Seremban, Malaysia
3 shared publications - Asuwani Maran
Hospital Tuanku Ja'afar, Seremban, Malaysia
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 20 (10) , 1430-1440
Multiplex PCR in pediatric LRTIs: challenges and opportunities in LMICs
Introduction: Lower respiratory tract infections (LRTIs) remain a leading cause of morbidity and mortality among children under five years of age, particularly in low- and middle- income countries (LMICs), where limitations in diagnostic capacity contribute to delayed and suboptimal clinical management. Conventional diagnostic methods are limited by slow turnaround time and reduced sensitivity, especially in mixed infections. This review synthesizes current evidence on the role of multiplex polymerase chain reaction (MxPCR) in the diagnosis and management of pediatric LRTIs, with emphasis on diagnostic accuracy, clinical impact, and implementation considerations in LMIC settings. Methodology: A narrative review of published literature was undertaken, focusing on studies evaluating MxPCR diagnostic performance, clinical outcomes, epidemiological insights, and cost-effectiveness in pediatric respiratory infections, with cross-reference to LMIC specific health system constraints. Observations: MxPCR consistently demonstrates high sensitivity and specificity for the detection of viral, bacterial, and mixed respiratory pathogens, enabling rapid and comprehensive pathogen identification. Evidence indicates improved antibiotic stewardship, reduced unnecessary investigations, and strengthened epidemiological surveillance. However, widespread adoption in LMICs remains limited by high per-test costs, infrastructure requirements, supply chain challenges, and limited local economic evaluation. Conclusions: MxPCR represents a valuable diagnostic advancement for pediatric LRTIs. Sustainable integration in LMICs will require context-specific cost-effectiveness studies, appropriate panel selection based on local epidemiology, and feasible funding. Until these conditions are met, selective use in tertiary or high-dependency pediatric settings, or case-by-case application based on severity, remains the most practical approach.
- 31 October 2026
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 20 (10) , 1430-1440
Open AccessMultiplex PCR in pediatric LRTIs: challenges and opportunities in LMICs
Introduction: Lower respiratory tract infections (LRTIs) remain a leading cause of morbidity and mortality among children under five years of age, particularly in low- and middle- income countries (LMICs), where limitations in diagnostic capacity contribute to delayed and suboptimal clinical management. Conventional diagnostic methods are limited by slow turnaround time and reduced sensitivity, especially in mixed infections. This review synthesizes current evidence on the role of multiplex polymerase chain reaction (MxPCR) in the diagnosis and management of pediatric LRTIs, with emphasis on diagnostic accuracy, clinical impact, and implementation considerations in LMIC settings. Methodology: A narrative review of published literature was undertaken, focusing on studies evaluating MxPCR diagnostic performance, clinical outcomes, epidemiological insights, and cost-effectiveness in pediatric respiratory infections, with cross-reference to LMIC specific health system constraints. Observations: MxPCR consistently demonstrates high sensitivity and specificity for the detection of viral, bacterial, and mixed respiratory pathogens, enabling rapid and comprehensive pathogen identification. Evidence indicates improved antibiotic stewardship, reduced unnecessary investigations, and strengthened epidemiological surveillance. However, widespread adoption in LMICs remains limited by high per-test costs, infrastructure requirements, supply chain challenges, and limited local economic evaluation. Conclusions: MxPCR represents a valuable diagnostic advancement for pediatric LRTIs. Sustainable integration in LMICs will require context-specific cost-effectiveness studies, appropriate panel selection based on local epidemiology, and feasible funding. Until these conditions are met, selective use in tertiary or high-dependency pediatric settings, or case-by-case application based on severity, remains the most practical approach.
- Open Access
- 15 October 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (10) , 762-772
Current review of pediatric Fas-associated death domain protein deficiency: expanding clinical and therapeutic perspectives
Fas-associated death domain protein (FADD) deficiency is a rare inborn error of immunity characterized by dysregulated T-cell proliferation. The clinical spectrum and management of FADD deficiency in children remain incompletely described. This review aimed to synthesize patient-level observational evidence on clinical manifestations, immunological and genetic findings, and treatment outcomes of pediatric patients with FADD deficiency. A literature search was conducted of PubMed, the Cochrane Library, and Scopus from database inception to July 2, 2026, and reference lists of eligible articles were reviewed. Inclusion criterion was articles on human clinical studies of patients with FADD gene mutation. Eligibility screening and data extraction were performed independently. Ten articles describing 18 patients were included. The reported ancestries included South Asian (n=9), European (n=6), and East/Central Asian (n=1). Parental consanguinity was reported in 10 of 12 patients (83.3%). Median age at onset was 0.8 years. Major presentations were fever-related encephalopathy, lymphoproliferation, and invasive pneumococcal disease. Common features included liver dysfunction, seizures, and functional hyposplenism. Regarding immunophenotyping, double-negative T cells were elevated in 9 of 10 patients (90%). Elevated soluble FAS ligand and interleukin-10 levels and defective lymphocyte apoptosis were observed in all tested patients; most patients had elevated vitamin B12 levels. The most common pathogenic variant was c.350G>A, followed by c.315T>G. Six patients died (33%) at a median age of 0.8 years. Mortality was high among patients with invasive pneumococcal disease; no deaths were reported among those with a lymphoproliferative phenotype or among the 2 hematopoietic stem cell transplantation recipients. FADD deficiency ranges from early-onset fever-related encephalopathy and fulminant sepsis to lymphoproliferative phenotypes. This review emphasizes the importance of recognizing FADD deficiency in children presenting with recurrent febrile encephalopathy, liver dysfunction, and a history of consanguinity and highlights prompt genetic evaluation and hematopoietic stem cell transplantation as potential curative therapies.
- 15 October 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (10) , 762-772
Open AccessCurrent review of pediatric Fas-associated death domain protein deficiency: expanding clinical and therapeutic perspectives
Fas-associated death domain protein (FADD) deficiency is a rare inborn error of immunity characterized by dysregulated T-cell proliferation. The clinical spectrum and management of FADD deficiency in children remain incompletely described. This review aimed to synthesize patient-level observational evidence on clinical manifestations, immunological and genetic findings, and treatment outcomes of pediatric patients with FADD deficiency. A literature search was conducted of PubMed, the Cochrane Library, and Scopus from database inception to July 2, 2026, and reference lists of eligible articles were reviewed. Inclusion criterion was articles on human clinical studies of patients with FADD gene mutation. Eligibility screening and data extraction were performed independently. Ten articles describing 18 patients were included. The reported ancestries included South Asian (n=9), European (n=6), and East/Central Asian (n=1). Parental consanguinity was reported in 10 of 12 patients (83.3%). Median age at onset was 0.8 years. Major presentations were fever-related encephalopathy, lymphoproliferation, and invasive pneumococcal disease. Common features included liver dysfunction, seizures, and functional hyposplenism. Regarding immunophenotyping, double-negative T cells were elevated in 9 of 10 patients (90%). Elevated soluble FAS ligand and interleukin-10 levels and defective lymphocyte apoptosis were observed in all tested patients; most patients had elevated vitamin B12 levels. The most common pathogenic variant was c.350G>A, followed by c.315T>G. Six patients died (33%) at a median age of 0.8 years. Mortality was high among patients with invasive pneumococcal disease; no deaths were reported among those with a lymphoproliferative phenotype or among the 2 hematopoietic stem cell transplantation recipients. FADD deficiency ranges from early-onset fever-related encephalopathy and fulminant sepsis to lymphoproliferative phenotypes. This review emphasizes the importance of recognizing FADD deficiency in children presenting with recurrent febrile encephalopathy, liver dysfunction, and a history of consanguinity and highlights prompt genetic evaluation and hematopoietic stem cell transplantation as potential curative therapies.
- Open Access
- 15 December 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (12) , 1007-1014
Clinical outcomes and healthcare utilization of hospitalized children with influenza versus COVID-19
Background: Influenza and coronavirus disease 2019 (COVID-19) are major causes of pediatric respiratory illness with overlapping clinical features but potentially differing impacts on healthcare utilization and outcomes.Purpose: To compare the clinical presentations, healthcare resource utilization, and outcomes of children hospitalized with influenza and COVID-19 and address the gaps in pediatric data from Southeast Asia.Methods: This retrospective observational study included children aged ≤12 years hospitalized with laboratory-confirmed influenza or COVID-19 at a tertiary hospital in Malaysia between May 1, 2022, and May 1, 2023. Patients with viral or bacterial coinfections were excluded. Influenza A and B cases were collectively analyzed. The patients' demographic data, clinical presentation, resource utilization, and outcomes were also evaluated. Propensity score matching (PSM) was performed to balance the cohorts for age, sex, ethnicity, and comorbidities. Outcomes were compared using standardized mean differences (SMDs).Results: A total of 299 patients were included (influenza, n=177; COVID-19, n=122). Patients with influenza were older (median, 3.6 years vs. 1.8 years; P<0.001) and more likely to have fever, cough, and rhinorrhea. COVID-19 patients presented earlier in the illness (median, 2 days vs. 4 days; P<0.001). After PSM, 102 patients were included in each group. Patients with influenza required greater healthcare resource use, including intravenous fluids (60.8% vs. 43.1%; SMD=0.36), empirical antibiotics (40.2% vs. 12.7%; SMD=0.66), respiratory support (40.2% vs. 26.5%, SMD=0.29), pediatric intensive care unit admission (10.8% vs. 2.9%; SMD=0.32), and longer duration of oxygen therapy (SMD=0.93).Conclusion: Children hospitalized for influenza demonstrated higher clinical severity and greater healthcare resource utilization than those hospitalized for COVID-19. These findings highlight the burden of influenza and inform hospital resource planning during periods of viral circulation.
- 15 December 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (12) , 1007-1014
Open AccessClinical outcomes and healthcare utilization of hospitalized children with influenza versus COVID-19
Background: Influenza and coronavirus disease 2019 (COVID-19) are major causes of pediatric respiratory illness with overlapping clinical features but potentially differing impacts on healthcare utilization and outcomes.Purpose: To compare the clinical presentations, healthcare resource utilization, and outcomes of children hospitalized with influenza and COVID-19 and address the gaps in pediatric data from Southeast Asia.Methods: This retrospective observational study included children aged ≤12 years hospitalized with laboratory-confirmed influenza or COVID-19 at a tertiary hospital in Malaysia between May 1, 2022, and May 1, 2023. Patients with viral or bacterial coinfections were excluded. Influenza A and B cases were collectively analyzed. The patients' demographic data, clinical presentation, resource utilization, and outcomes were also evaluated. Propensity score matching (PSM) was performed to balance the cohorts for age, sex, ethnicity, and comorbidities. Outcomes were compared using standardized mean differences (SMDs).Results: A total of 299 patients were included (influenza, n=177; COVID-19, n=122). Patients with influenza were older (median, 3.6 years vs. 1.8 years; P<0.001) and more likely to have fever, cough, and rhinorrhea. COVID-19 patients presented earlier in the illness (median, 2 days vs. 4 days; P<0.001). After PSM, 102 patients were included in each group. Patients with influenza required greater healthcare resource use, including intravenous fluids (60.8% vs. 43.1%; SMD=0.36), empirical antibiotics (40.2% vs. 12.7%; SMD=0.66), respiratory support (40.2% vs. 26.5%, SMD=0.29), pediatric intensive care unit admission (10.8% vs. 2.9%; SMD=0.32), and longer duration of oxygen therapy (SMD=0.93).Conclusion: Children hospitalized for influenza demonstrated higher clinical severity and greater healthcare resource utilization than those hospitalized for COVID-19. These findings highlight the burden of influenza and inform hospital resource planning during periods of viral circulation.
- Open Access
- 30 November 2025
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 40 (4) , 567-573
Utility of procalcitonin in diagnosing early postoperative sepsis after pediatric cardiac surgery in Malaysia
Background: Systemic inflammation following cardiopulmonary bypass (CPB) can interfere with analysis of routine clinical and biochemical parameters. Procalcitonin (PCT) is a potential biomarker for diagnosing early postoperative sepsis in pediatric patients following cardiac surgery utilizing CPB. This study aimed to evaluate the diagnostic accuracy of PCT compared to other biomarkers, especially C-reactive protein (CRP), in this clinical setting. Methods: A prospective single-center study was conducted over a 10-month period during the coronavirus disease 2019 (COVID-19) pandemic (2021–2022), enrolling 89 pediatric patients postcardiac surgery. PCT, CRP, and complete blood count were analyzed, and area under the curve (AUC) was employed for statistical analysis. Results: PCT and CRP demonstrated moderate discriminatory ability with AUCs of 0.678 and 0.635, respectively. White cell count exhibited fair discriminatory power, and platelet count performed poorly in distinguishing septic from nonseptic cases (AUC: white cell count, 0.545; platelet, 0.486). Conclusions: PCT and CRP hold promise as diagnostic markers for early postoperative sepsis in pediatric cardiac surgery patients. However, these biomarkers are not adequate standalone indicators, emphasizing the continued need for clinical judgment supported by multiple diagnostic parameters.
- 30 November 2025
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 40 (4) , 567-573
Open AccessUtility of procalcitonin in diagnosing early postoperative sepsis after pediatric cardiac surgery in Malaysia
Background: Systemic inflammation following cardiopulmonary bypass (CPB) can interfere with analysis of routine clinical and biochemical parameters. Procalcitonin (PCT) is a potential biomarker for diagnosing early postoperative sepsis in pediatric patients following cardiac surgery utilizing CPB. This study aimed to evaluate the diagnostic accuracy of PCT compared to other biomarkers, especially C-reactive protein (CRP), in this clinical setting. Methods: A prospective single-center study was conducted over a 10-month period during the coronavirus disease 2019 (COVID-19) pandemic (2021–2022), enrolling 89 pediatric patients postcardiac surgery. PCT, CRP, and complete blood count were analyzed, and area under the curve (AUC) was employed for statistical analysis. Results: PCT and CRP demonstrated moderate discriminatory ability with AUCs of 0.678 and 0.635, respectively. White cell count exhibited fair discriminatory power, and platelet count performed poorly in distinguishing septic from nonseptic cases (AUC: white cell count, 0.545; platelet, 0.486). Conclusions: PCT and CRP hold promise as diagnostic markers for early postoperative sepsis in pediatric cardiac surgery patients. However, these biomarkers are not adequate standalone indicators, emphasizing the continued need for clinical judgment supported by multiple diagnostic parameters.
- Open Access
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (3) , 402-411
Clinical Burden of Pediatric Influenza A and B in Malaysia: Outcomes and Resource Utilization in A Tropical Setting
Mohan VA, et al. Infect Chemother. 2025 Sep;57:e55. https://doi.org/10.3947/ic.2025.0069
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (3) , 402-411
Open AccessClinical Burden of Pediatric Influenza A and B in Malaysia: Outcomes and Resource Utilization in A Tropical Setting
Mohan VA, et al. Infect Chemother. 2025 Sep;57:e55. https://doi.org/10.3947/ic.2025.0069
- Open Access
- 26 March 2024
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 18 (3) , e13747
Clinical comparison of HMPV and RSV infections in hospitalised Malaysian children: A propensity score matched study
Introduction: Human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) are significant contributors to the burden of acute respiratory infections in children, but data on hMPV from Southeast Asia are limited despite its potential for serious disease. This study aimed to compare the clinical presentation, resource utilisation and outcomes between hMPV and RSV infections in hospitalised Malaysian children.Methods: This retrospective, observational study included children aged ≤12 years old hospitalised with hMPV or RSV, confirmed via direct fluorescent antibody (DFA) methods, between 1 July to 30 October 2022 at Hospital Tuanku Ja'afar Seremban, Malaysia. Demographic, clinical presentation, resource utilisation and outcome data were analysed. Propensity score matching was used to balance cohorts based on key demographic and clinical characteristics.Results: This study included 192 patients, comprising 112 with hMPV and 80 with RSV. hMPV patients were older (median age 20.5 vs. 9.4 months, p < 0.001) and had a higher incidence of comorbidities (24.1% vs. 7.5%, p = 0.003). Fever was more common in the hMPV group (97.3% vs. 73.8%, p < 0.001), but the other clinical manifestations were similar. Postmatching analysis showed higher corticosteroid use in the hMPV group (p = 0.01). No significant differences were observed in the use of other resources, PICU admissions, duration of hospitalisation or mortality rates between both groups.Conclusion: hMPV and RSV infections in children share similar clinical manifestations and outcomes, with hMPV affecting older children and showing higher corticosteroid usage. These findings emphasise the need for equal clinical vigilance for both hMPV and RSV in paediatric respiratory infections.
- 26 March 2024
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 18 (3) , e13747
Open AccessClinical comparison of HMPV and RSV infections in hospitalised Malaysian children: A propensity score matched study
Introduction: Human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) are significant contributors to the burden of acute respiratory infections in children, but data on hMPV from Southeast Asia are limited despite its potential for serious disease. This study aimed to compare the clinical presentation, resource utilisation and outcomes between hMPV and RSV infections in hospitalised Malaysian children.Methods: This retrospective, observational study included children aged ≤12 years old hospitalised with hMPV or RSV, confirmed via direct fluorescent antibody (DFA) methods, between 1 July to 30 October 2022 at Hospital Tuanku Ja'afar Seremban, Malaysia. Demographic, clinical presentation, resource utilisation and outcome data were analysed. Propensity score matching was used to balance cohorts based on key demographic and clinical characteristics.Results: This study included 192 patients, comprising 112 with hMPV and 80 with RSV. hMPV patients were older (median age 20.5 vs. 9.4 months, p < 0.001) and had a higher incidence of comorbidities (24.1% vs. 7.5%, p = 0.003). Fever was more common in the hMPV group (97.3% vs. 73.8%, p < 0.001), but the other clinical manifestations were similar. Postmatching analysis showed higher corticosteroid use in the hMPV group (p = 0.01). No significant differences were observed in the use of other resources, PICU admissions, duration of hospitalisation or mortality rates between both groups.Conclusion: hMPV and RSV infections in children share similar clinical manifestations and outcomes, with hMPV affecting older children and showing higher corticosteroid usage. These findings emphasise the need for equal clinical vigilance for both hMPV and RSV in paediatric respiratory infections.
- 1 January 2024
- Published by Wiley in Pediatrics International
- Vol. 66 (1) , e15777
Clinical severity of Omicron and Delta SARS‐CoV‐2 infections in children
Background: We aimed to compare the clinical features and severity of the Omicron and Delta variant infections among children hospitalized for coronavirus disease 2019 (COVID‐19). Methods: Children 12 years old or less hospitalized for COVID‐19 across five hospitals between January 1, 2021 and March 31, 2022 were identified using the state's pediatric COVID‐19 registry. Delta and Omicron‐infected patients without previous COVID‐19 infection, COVID‐19 vaccination, or co‐infections were propensity‐score matched 1:1 to control for differences in baseline characteristics. Clinical manifestations, treatments, and outcomes were analyzed. Disease severity was assessed using an adapted WHO ordinal scale. Results: Of the initial 1367 patients, 668 had Delta infection and 699 had Omicron infection. Propensity‐score matching produced 558 matched pairs. Patients with Omicron infection were more likely to present with croup (the odds ratio, OR, was 10.87, with a 95% confidence interval, CI, ranging from 2.54 to 46.59), lower respiratory tract infection (OR 2.32, 95% CI, 1.48–3.64) and seizures (OR 8.39, 95% CI, 5.04–13.99) compared with those with Delta infection. Omicron was associated with increased odds of moderate/severe disease (OR 6.14, 95% CI, 4.72–7.99) and a greater need for intravenous fluid therapy (OR 6.00, 95% CI, 4.29–8.39), corticosteroids (OR 3.08, 95% CI, 1.66–5.72), empirical antibiotics (OR 1.70, 95% CI, 1.10–2.64), and low‐flow nasal oxygen therapy (OR 3.68, 95% CI, 2.17–6.22) in comparison with Delta. Conclusion: Children hospitalized with Omicron infection demonstrated a distinct clinical profile compared to those with Delta infection, with increased likelihood of moderate/severe disease and higher utilization of health‐care resources.
- 1 January 2024
- Published by Wiley in Pediatrics International
- Vol. 66 (1) , e15777
Clinical severity of Omicron and Delta SARS‐CoV‐2 infections in children
Background: We aimed to compare the clinical features and severity of the Omicron and Delta variant infections among children hospitalized for coronavirus disease 2019 (COVID‐19). Methods: Children 12 years old or less hospitalized for COVID‐19 across five hospitals between January 1, 2021 and March 31, 2022 were identified using the state's pediatric COVID‐19 registry. Delta and Omicron‐infected patients without previous COVID‐19 infection, COVID‐19 vaccination, or co‐infections were propensity‐score matched 1:1 to control for differences in baseline characteristics. Clinical manifestations, treatments, and outcomes were analyzed. Disease severity was assessed using an adapted WHO ordinal scale. Results: Of the initial 1367 patients, 668 had Delta infection and 699 had Omicron infection. Propensity‐score matching produced 558 matched pairs. Patients with Omicron infection were more likely to present with croup (the odds ratio, OR, was 10.87, with a 95% confidence interval, CI, ranging from 2.54 to 46.59), lower respiratory tract infection (OR 2.32, 95% CI, 1.48–3.64) and seizures (OR 8.39, 95% CI, 5.04–13.99) compared with those with Delta infection. Omicron was associated with increased odds of moderate/severe disease (OR 6.14, 95% CI, 4.72–7.99) and a greater need for intravenous fluid therapy (OR 6.00, 95% CI, 4.29–8.39), corticosteroids (OR 3.08, 95% CI, 1.66–5.72), empirical antibiotics (OR 1.70, 95% CI, 1.10–2.64), and low‐flow nasal oxygen therapy (OR 3.68, 95% CI, 2.17–6.22) in comparison with Delta. Conclusion: Children hospitalized with Omicron infection demonstrated a distinct clinical profile compared to those with Delta infection, with increased likelihood of moderate/severe disease and higher utilization of health‐care resources.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15690
Epidemiology, clinical characteristics and outcomes of multisystem inflammatory syndrome in children
Background: We describe the epidemiology, clinical characteristics, and outcomes of multisystem inflammatory syndrome in children (MIS‐C) among children from Negeri Sembilan, Malaysia.Methods: A retrospective, multicentre, observational study was performed among children ≤15 years old who were hospitalized for MIS‐C between January 18, 2021 and June 30, 2023. The incidence of MIS‐C was estimated using reported SARS‐CoV‐2 cases and census population data. Descriptive analyses were used to summarize the clinical presentation and outcomes.Results: The study included 53 patients with a median age of 5.7 years (IQR 1.8–8.7 years); 75.5% were males. The overall incidence of MIS‐C was approximately 5.9 cases per 1,000,000 person‐months. Pediatric intensive care unit (PICU) admission was required for 22 (41.5%) patients. No mortalities were recorded. Children aged 6–12 years were more likely to present with cardiac dysfunction/shock (odds ratio [OR] 5.43, 95% confidence interval [CI] 1.67–17.66), whereas children below 6 years were more likely to present with a Kawasaki disease phenotype (OR 5.50, 95% CI 1.33–22.75). Twenty patients (37.7%) presented with involvement of at least four organ systems, but four patients (7.5%) demonstrated single‐organ system involvement.Conclusion: An age‐based variation in the clinical presentation of MIS‐C was demonstrated. Our findings suggest MIS‐C could manifest in a spectrum, including single‐organ involvement. Despite the high requirement for PICU admission, the prognosis of MIS‐C was favorable, with no recorded mortalities.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15690
Epidemiology, clinical characteristics and outcomes of multisystem inflammatory syndrome in children
Background: We describe the epidemiology, clinical characteristics, and outcomes of multisystem inflammatory syndrome in children (MIS‐C) among children from Negeri Sembilan, Malaysia.Methods: A retrospective, multicentre, observational study was performed among children ≤15 years old who were hospitalized for MIS‐C between January 18, 2021 and June 30, 2023. The incidence of MIS‐C was estimated using reported SARS‐CoV‐2 cases and census population data. Descriptive analyses were used to summarize the clinical presentation and outcomes.Results: The study included 53 patients with a median age of 5.7 years (IQR 1.8–8.7 years); 75.5% were males. The overall incidence of MIS‐C was approximately 5.9 cases per 1,000,000 person‐months. Pediatric intensive care unit (PICU) admission was required for 22 (41.5%) patients. No mortalities were recorded. Children aged 6–12 years were more likely to present with cardiac dysfunction/shock (odds ratio [OR] 5.43, 95% confidence interval [CI] 1.67–17.66), whereas children below 6 years were more likely to present with a Kawasaki disease phenotype (OR 5.50, 95% CI 1.33–22.75). Twenty patients (37.7%) presented with involvement of at least four organ systems, but four patients (7.5%) demonstrated single‐organ system involvement.Conclusion: An age‐based variation in the clinical presentation of MIS‐C was demonstrated. Our findings suggest MIS‐C could manifest in a spectrum, including single‐organ involvement. Despite the high requirement for PICU admission, the prognosis of MIS‐C was favorable, with no recorded mortalities.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15565
Clinical characteristics of COVID‐19 in hospitalized young infants and risk factors for disease severity
Background: This study aimed to describe the clinical characteristics and severity of young infants hospitalized with COVID‐19 and study the relationship between breastfeeding and maternal COVID‐19 vaccination on the severity of COVID‐19.Methods: A retrospective, observational study was performed among infants aged 6 months and below hospitalized for COVID‐19 in a tertiary state hospital in Malaysia between February 1 and April 30, 2022. The primary outcome was “serious disease,” defined as pneumonia requiring respiratory support or dehydration with warning signs. Multivariate logistic regression was used to determine independent predictors for serious disease.Results: A total of 102 infants were included in the study; 53.9% were males with a median age of 11 weeks (interquartile range: 5–20 weeks). Sixteen patients (15.7%) had pre‐existing comorbidities, including preterm birth. Fever was the most common presenting symptom (82.4%), followed by cough (53.9%), and rhinorrhea (31.4%). Forty‐one infants (40.2%) presented with serious disease, warranting either respiratory support or intravenous fluid therapy for dehydration. Recent maternal COVID‐19 vaccination was associated with a reduced risk of serious disease on univariate analysis but was not significant after multivariate adjustment (adjusted odds ratio [aOR] 0.39; 95% CI: 0.14–1.11; p = 0.08). Exclusive breastfeeding was protective against serious COVID‐19 in young infants, independent of other confounding factors (aOR 0.21, 95% CI: 0.06–0.71; p = 0.01).Conclusion: COVID‐19 is a serious disease with non‐specific clinical manifestations in young infants. Exclusive breastfeeding could play an important protective role.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15565
Clinical characteristics of COVID‐19 in hospitalized young infants and risk factors for disease severity
Background: This study aimed to describe the clinical characteristics and severity of young infants hospitalized with COVID‐19 and study the relationship between breastfeeding and maternal COVID‐19 vaccination on the severity of COVID‐19.Methods: A retrospective, observational study was performed among infants aged 6 months and below hospitalized for COVID‐19 in a tertiary state hospital in Malaysia between February 1 and April 30, 2022. The primary outcome was “serious disease,” defined as pneumonia requiring respiratory support or dehydration with warning signs. Multivariate logistic regression was used to determine independent predictors for serious disease.Results: A total of 102 infants were included in the study; 53.9% were males with a median age of 11 weeks (interquartile range: 5–20 weeks). Sixteen patients (15.7%) had pre‐existing comorbidities, including preterm birth. Fever was the most common presenting symptom (82.4%), followed by cough (53.9%), and rhinorrhea (31.4%). Forty‐one infants (40.2%) presented with serious disease, warranting either respiratory support or intravenous fluid therapy for dehydration. Recent maternal COVID‐19 vaccination was associated with a reduced risk of serious disease on univariate analysis but was not significant after multivariate adjustment (adjusted odds ratio [aOR] 0.39; 95% CI: 0.14–1.11; p = 0.08). Exclusive breastfeeding was protective against serious COVID‐19 in young infants, independent of other confounding factors (aOR 0.21, 95% CI: 0.06–0.71; p = 0.01).Conclusion: COVID‐19 is a serious disease with non‐specific clinical manifestations in young infants. Exclusive breastfeeding could play an important protective role.
- Open Access
- 1 November 2021
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 58 (5) , 769-773
Risk factors associated with household transmission of SARS‐CoV‐2 in Negeri Sembilan, Malaysia
Aim Households are a significant venue for the transmission of SARS-CoV-2. We conducted a study to characterise the transmission dynamics and identify risk factors for household transmission of SARS-CoV-2 in Negeri Sembilan, Malaysia. Methods This retrospective observational study included 185 families of paediatric COVID-19 cases from 1 February 2020 to 31 December 2020. We identified the index case for each household and gathered the socio-demographic, epidemiological investigation results and risk factors for household transmission from medical case records. The secondary attack rate was calculated, and logistic regression analyses were used to identify risk factors associated with secondary household transmission of SARS-CoV-2. Results Of the 848 household contacts, 466 acquired secondary infections, resulting in a secondary attack rate of 55%. The median age of the secondary cases was 12 years. Female household contacts and household contacts who slept in the same room with the index case were significantly associated with increased risk for COVID-19. Other independent risk factors associated with higher transmission risk in the household included an index case who was symptomatic, a household index case aged greater than 18 years and a male household index case. Conclusions High rates of household transmission of COVID-19 were found, indicating households were a major setting of transmission of SARS-CoV-2. Our data provide insight into the risk factors for household transmission of SARS-CoV-2 in Malaysia.
- 1 November 2021
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 58 (5) , 769-773
Open AccessRisk factors associated with household transmission of SARS‐CoV‐2 in Negeri Sembilan, Malaysia
Aim Households are a significant venue for the transmission of SARS-CoV-2. We conducted a study to characterise the transmission dynamics and identify risk factors for household transmission of SARS-CoV-2 in Negeri Sembilan, Malaysia. Methods This retrospective observational study included 185 families of paediatric COVID-19 cases from 1 February 2020 to 31 December 2020. We identified the index case for each household and gathered the socio-demographic, epidemiological investigation results and risk factors for household transmission from medical case records. The secondary attack rate was calculated, and logistic regression analyses were used to identify risk factors associated with secondary household transmission of SARS-CoV-2. Results Of the 848 household contacts, 466 acquired secondary infections, resulting in a secondary attack rate of 55%. The median age of the secondary cases was 12 years. Female household contacts and household contacts who slept in the same room with the index case were significantly associated with increased risk for COVID-19. Other independent risk factors associated with higher transmission risk in the household included an index case who was symptomatic, a household index case aged greater than 18 years and a male household index case. Conclusions High rates of household transmission of COVID-19 were found, indicating households were a major setting of transmission of SARS-CoV-2. Our data provide insight into the risk factors for household transmission of SARS-CoV-2 in Malaysia.